Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332228 · ClinicalTrials.gov registry record · Phase 2
Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00332228 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 125 participants.
The verdict
NCT00332228, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
The overall goal of this research project is to test the efficacy of a newly developed therapy, Behavioral Naltrexone Therapy (BNT), to enhance the success of naltrexone maintenance and long-term abstinence for individuals with heroin dependence. This study includes free detox and outpatient treatment for opioid dependence that includes medication and a behavioral intervention.
Interventions
- DRUG depot naltrexone
- BEHAVIORAL Compliance enhancement (CE)
- DRUG BNT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2002-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332228
The ClinicalTrials.gov registry entry for NCT00332228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which depot naltrexone is the first listed.
NCT00332228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332228 about?
NCT00332228 is a clinical study titled "Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence". The overall goal of this research project is to test the efficacy of a newly developed therapy, Behavioral Naltrexone Therapy (BNT), to enhance the success of naltrexone maintenance and long-term abstinence for individuals with heroin dependence. This study includes free detox and outpatient treatme...
What is the current status of trial NCT00332228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2002-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00332228?
The interventions under investigation include: depot naltrexone (DRUG), Compliance enhancement (CE) (BEHAVIORAL), BNT (DRUG).
Who is sponsoring clinical trial NCT00332228?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.